

Resource Summary Report

Generated by [RRID](#) on Apr 10, 2025

NeuroBiobank Munich

RRID:SCR_005014

Type: Tool

Proper Citation

NeuroBiobank Munich (RRID:SCR_005014)

Resource Information

URL: http://www.tmf-ev.de/BiobankenRegisterEN/Registry.aspx?udt_2021_param_detail=84

Proper Citation: NeuroBiobank Munich (RRID:SCR_005014)

Description: A brain bank which collects brain tissue from patients who died from various neurological and psychiatric diseases. These tissues are available for biochemical, molecular biological, and other work groups with the aim of supporting research on the pathogenesis, diagnosis, and therapy of these diseases. Collected brains are clinically and neuropathologically well-characterized. The collection and distribution of brain tissue samples is an ongoing process. NeuroBiobank Munich offers help with the organization and implementation of autopsies as well as with the neuropathologic diagnostics. The thematic emphasis of the NeuroBiobank Munich is Parkinson's disease and demential degenerative disorders such as Alzheimer's disease or Creutzfeldt-Jakob disease. NeuroBiobank Munich coordinates the German national brain tissue bank (BrainNet) and the European brain tissue bank (BrainNet Europe).

Abbreviations: NBM

Synonyms: ZNP Biobank

Resource Type: biomaterial supply resource, tissue bank, material resource

Keywords: brain, tissue, brain bank, neurological disease, mental disease, parkinson's disease, alzheimer's disease, creutzfeldt-jakob syndrome, post mortem, neurodegenerative disease, dementia

Related Condition: Parkinson's disease, Alzheimer's disease, Creutzfeldt-Jakob Syndrome, Neurodegenerative disease, Dementia

Funding:**Availability:** Public**Resource Name:** NeuroBiobank Munich**Resource ID:** SCR_005014**Alternate IDs:** nlx_144006**Record Creation Time:** 20220129T080227+0000**Record Last Update:** 20250410T065222+0000

Ratings and Alerts

No rating or validation information has been found for NeuroBiobank Munich.

No alerts have been found for NeuroBiobank Munich.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 26 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#).

Majerníková N, et al. (2024) The link between amyloid ? and ferroptosis pathway in Alzheimer's disease progression. *Cell death & disease*, 15(10), 782.

N M P, et al. (2024) A multi-region single nucleus transcriptomic atlas of Parkinson's disease. *Scientific data*, 11(1), 1274.

Jäkel L, et al. (2024) Altered brain expression and cerebrospinal fluid levels of TIMP4 in cerebral amyloid angiopathy. *Acta neuropathologica communications*, 12(1), 103.

Lee JD, et al. (2024) Cognition-associated long noncoding RNAs are dysregulated upon severe COVID-19. *Frontiers in immunology*, 15, 1290523.

Ainslie AP, et al. (2024) Glioblastoma and its treatment are associated with extensive accelerated brain aging. *Aging cell*, 23(3), e14066.

Gomez Ramos B, et al. (2024) Multiomics analysis identifies novel facilitators of human

dopaminergic neuron differentiation. *EMBO reports*, 25(1), 254.

Lin NH, et al. (2024) Glial fibrillary acidic protein is pathologically modified in Alexander disease. *The Journal of biological chemistry*, 300(7), 107402.

Song X, et al. (2024) RNA splicing analysis deciphers developmental hierarchies and reveals therapeutic targets in adult glioma. *The Journal of clinical investigation*, 134(11).

De Rijk P, et al. (2024) Scywalker: scalable end-to-end data analysis workflow for long-read single-cell transcriptome sequencing. *Bioinformatics (Oxford, England)*, 40(9).

Vandiver AR, et al. (2023) Nanopore sequencing identifies a higher frequency and expanded spectrum of mitochondrial DNA deletion mutations in human aging. *Aging cell*, 22(6), e13842.

Hirschberg Y, et al. (2023) Proteomic comparison between non-purified cerebrospinal fluid and cerebrospinal fluid-derived extracellular vesicles from patients with Alzheimer's, Parkinson's and Lewy body dementia. *Journal of extracellular vesicles*, 12(12), e12383.

Irmady K, et al. (2023) Blood transcriptomic signatures associated with molecular changes in the brain and clinical outcomes in Parkinson's disease. *Nature communications*, 14(1), 3956.

Aksoylu I, et al. (2023) Translatome analysis of Tuberous Sclerosis Complex-1 patient-derived neural progenitor cells reveal rapamycin-dependent and independent alterations. *Research square*.

Heylen A, et al. (2023) Brain Kynurenine Pathway Metabolite Levels May Reflect Extent of Neuroinflammation in ALS, FTD and Early Onset AD. *Pharmaceuticals (Basel, Switzerland)*, 16(4).

Aksoylu IS, et al. (2023) Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations. *Molecular autism*, 14(1), 39.

Zeng C, et al. (2023) Dissection of transcriptomic and epigenetic heterogeneity of grade 4 gliomas: implications for prognosis. *Acta neuropathologica communications*, 11(1), 133.

Koning ACAM, et al. (2022) Mineralocorticoid receptor status in the human brain after dexamethasone treatment: a single case study. *Endocrine connections*, 11(3).

Solas M, et al. (2021) 5-HT7 receptors in Alzheimer's disease. *Neurochemistry international*, 150, 105185.

Gerrits E, et al. (2021) Distinct amyloid- β and tau-associated microglia profiles in Alzheimer's disease. *Acta neuropathologica*, 141(5), 681.

Lu L, et al. (2020) Robust Hi-C Maps of Enhancer-Promoter Interactions Reveal the Function of Non-coding Genome in Neural Development and Diseases. *Molecular cell*, 79(3), 521.